Literature DB >> 16166292

WT1 induces apoptosis through transcriptional regulation of the proapoptotic Bcl-2 family member Bak.

Debra J Morrison1, Milton A English, Jonathan D Licht.   

Abstract

Wilms' tumor or nephroblastoma is believed to arise from embryonic nephrogenic rests of multipotent cells that fail to terminally differentiate into epithelium and continue to proliferate. The WT1 tumor suppressor gene, a transcription factor controlling the mesenchymal-epithelial transition in renal development, is mutated in 10% to 15% of Wilms' tumors. This potentially explains the disordered differentiation and proliferation program of a subset of Wilms' tumors. To elucidate the role of mutations of WT1 in the etiology of Wilms' tumor, we used an inducible cellular system for expressing wild-type and tumor-derived missense mutant WT1 proteins. Expression of wild-type WT1, but not mutant proteins, blocked cellular proliferation and DNA synthesis and rapidly induced apoptosis. We showed that wild-type WT1 induced transcription of one of the seven studied proapoptotic genes, Bak. Furthermore, WT1 protein bound to specific DNA-binding sites located in the Bak promoter and Bak was critical to WT1-mediated apoptosis, as overexpression of VDAC2, a specific Bak inhibitor, attenuated WT1-mediated cell death. These data support the hypothesis that Wilms' tumors arise, in part, because WT1 mutant proteins fail to promote programmed cell death during kidney development.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16166292     DOI: 10.1158/0008-5472.CAN-04-3657

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  27 in total

Review 1.  Candidate genes and potential targets for therapeutics in Wilms' tumour.

Authors:  Christopher Blackmore; Max J Coppes; Aru Narendran
Journal:  Clin Transl Oncol       Date:  2010-09       Impact factor: 3.405

2.  An integrated genome screen identifies the Wnt signaling pathway as a major target of WT1.

Authors:  Marianne K-H Kim; Thomas J McGarry; Pilib O Broin; Jared M Flatow; Aaron A-J Golden; Jonathan D Licht
Journal:  Proc Natl Acad Sci U S A       Date:  2009-06-22       Impact factor: 11.205

3.  Dasatinib and navitoclax act synergistically to target NUP98-NSD1+/FLT3-ITD+ acute myeloid leukemia.

Authors:  Jarno L Kivioja; Angeliki Thanasopoulou; Ashwini Kumar; Mika Kontro; Bhagwan Yadav; Muntasir M Majumder; Komal K Javarappa; Samuli Eldfors; Juerg Schwaller; Kimmo Porkka; Caroline A Heckman
Journal:  Leukemia       Date:  2018-12-19       Impact factor: 11.528

4.  A novel missense mutation of Wilms' Tumor 1 causes autosomal dominant FSGS.

Authors:  Gentzon Hall; Rasheed A Gbadegesin; Peter Lavin; Guanghong Wu; Yangfan Liu; Edwin C Oh; Liming Wang; Robert F Spurney; Jason Eckel; Thomas Lindsey; Alison Homstad; Andrew F Malone; Paul J Phelan; Andrey Shaw; David N Howell; Peter J Conlon; Nicholas Katsanis; Michelle P Winn
Journal:  J Am Soc Nephrol       Date:  2014-08-21       Impact factor: 10.121

5.  Bcl-X(L) is the primary mediator of p21 protection against hyperoxia-induced cell death.

Authors:  Yu-Chieh M Wu; Michael A O'Reilly
Journal:  Exp Lung Res       Date:  2010-12-04       Impact factor: 2.459

6.  Differential regulation of the proapoptotic multidomain protein Bak by p53 and p73 at the promoter level.

Authors:  V Graupner; E Alexander; T Overkamp; O Rothfuss; V De Laurenzi; B F Gillissen; P T Daniel; K Schulze-Osthoff; F Essmann
Journal:  Cell Death Differ       Date:  2011-01-14       Impact factor: 15.828

7.  HtrA2, taming the oncogenic activities of WT1.

Authors:  Jörg Hartkamp; Stefan G E Roberts
Journal:  Cell Cycle       Date:  2010-07-01       Impact factor: 4.534

8.  The Wilms' tumor suppressor protein WT1 is processed by the serine protease HtrA2/Omi.

Authors:  Jörg Hartkamp; Brian Carpenter; Stefan G E Roberts
Journal:  Mol Cell       Date:  2010-01-29       Impact factor: 17.970

9.  The antiapoptotic gene A1/BFL1 is a WT1 target gene that mediates granulocytic differentiation and resistance to chemotherapy.

Authors:  Lesley A Simpson; Emily A Burwell; Kida A Thompson; Samira Shahnaz; Allen R Chen; David M Loeb
Journal:  Blood       Date:  2006-02-16       Impact factor: 22.113

10.  A pathologic link between Wilms tumor suppressor gene, WT1, and IFI16.

Authors:  Marianne K-H Kim; Jacqueline M Mason; Chi-Ming Li; Windy Berkofsky-Fessler; Le Jiang; Divaker Choubey; Paul E Grundy; Benjamin Tycko; Jonathan D Licht
Journal:  Neoplasia       Date:  2008-01       Impact factor: 5.715

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.